Human lactoferrin derived peptide for use as an antigen masking agent

Patent metadata

Field	Value
Publication number	US-9724422-B2
Application number	US-201013988829-A
Country	US
Kind code	B2
Filing date	Nov 26, 2010
Priority date	Nov 26, 2010
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

The invention refers to a human lactoferrin derived peptide for use as an antigen masking agent in the production of a pharmaceutical composition for delivery of a biological active substance in a mammalian organism, where the biological active substance is able to induce an undesired immune response by the mammalian organism, where the pharmaceutical composition comprises a supramolecular aggregate of the biological active substance and the human lactoferrin derived peptide, with the effect that after delivery of pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance.

First claim

The invention claimed is:

1. A pharmaceutical composition, comprising:
a supramolecular aggregate of a biological active substance and a human lactoferrin derived peptide,
wherein the human lactoferrin derived peptide consists of the amino acid sequence of KCFQWQRNMRKVRGPPVSCIKR (SEQ ID NO: 1) or a sequence which is at least 90% homologous to SEQ ID NO: 1,
wherein the biological active substance induces an undesired immune response by a mammalian organism, with an effect that after delivery of the pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance, and
wherein the biological active substance is in a sample of blood which is transfused to the mammalian organism.

2. The composition according to claim 1 , wherein the human lactoferrin derived peptide consists of a sequence that is at least 90% homologous to SEQ ID NO: 1, and cysteine residues in positions 2 and 19 are present.

3. The composition according to claim 2 , wherein the undesired immune response is an IgG immune response.

4. The composition according to claim 2 , wherein the undesired immune response is an IgE immune response.

5. The composition according to claim 2 , wherein the biological active substance is selected from the group consisting of a biological active protein, a biological active peptide, an antisera antibody, a polyclonal antibody, and a monoclonal antibody.

6. The composition according to claim 1 , wherein the undesired immune response is an IgG immune response.

7. The composition according to claim 6 , wherein the biological active substance is selected from the group consisting of a biological active protein, a biological active peptide, an antisera antibody, a polyclonal antibody, and a monoclonal antibody.

8. The composition according to claim 1 , wherein the undesired immune response is an IgE immune response.

9. The composition according to claim 1 , wherein the biological active substance is selected from the group consisting of a biological active protein, a biological active peptide, an antisera antibody, a polyclonal antibody, and a monoclonal antibody.

10. The composition according to claim 1 , wherein the biological active substance is in or on a surface of an organ which is transplanted to the mammalian organism.

11. The composition according to claim 1 , wherein the biological active substance and the human lactoferrin derived peptide are not covalently bound to each other in the supramolecular aggregate.

12. The composition according to claim 1 , wherein the biological active substance and the human lactoferrin derived peptide are covalently bound to each other in the supramolecular aggregate.

13. The composition according to claim 1 , wherein the human lactoferrin derived peptide consists of the amino acid sequence of SEQ ID NO: 1 or a sequence which is at least 95% homologous to SEQ ID NO: 1.

14. A pharmaceutical composition, comprising:
a supramolecular aggregate of a biological active substance and a human lactoferrin derived peptide,
wherein the human lactoferrin derived peptide consists of the amino acid sequence of KCFQWQRNMRKVRGPPVSCIKR (SEQ ID NO: 1) or a sequence which is at least 90% homologous to SEQ ID NO: 1,
wherein the biological active substance induces an undesired immune response by a mammalian organism, with an effect that after delivery of the pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance, and
wherein the biological active substance is in or on a surface of an organ which is transplanted to the mammalian organism.

15. The composition according to claim 14 , wherein the human lactoferrin derived peptide consists of the amino acid sequence of SEQ ID NO: 1 or a sequence which is at least 95% homologous to SEQ ID NO: 1.

Assignees

• Hartwig Benedikt
• Tome Alcalde Juan
• Windhab Norbert
• Ansuategui Panzano Maria Del Pilar
• Vara Carrera Matias Javier
• Evonik Roehm Gmbh

Inventors

• Hartwig Benedikt
• Tome Alcalde Juan
• Windhab Norbert
• Ansuategui Panzano Maria Del Pilar
• Vara Carrera Matias Javier

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61K38/40

  Transferrins, e.g. lactoferrins, ovotransferrins · CPC title

• A61K38/1703

  from vertebrates · CPC title

• C07K14/79 Primary

  Transferrins, e.g. lactoferrins, ovotransferrins · CPC title